BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2026-11

189 industry Phase 2/3 trial readout(s) and 20 FDA decision event(s). Past days: any status; from today on: active trials only.

← 2026-10 | 2026-12 →

FDA decision events

DateEventStatusCompanyDrugSource
2026-11-01 (month)PDUFA date (company-disclosed)date passedMoonLake Immunotherapeutics MLTXPDUFA November 2026 - MoonLake Immunotherapeutics
2026-11-05FDA approvalapprovedJANSSEN BIOTECHRYBREVANT FASPROApproved 2026-11-05: RYBREVANT FASPRO (BLA761433 SUPPL2)
2026-11-09FDA approvalapprovedAVYXA HOLDINGSOXDERYSApproved 2026-11-09: OXDERYS (NDA221093 ORIG1)
2026-11-09FDA approvalapprovedBAYER HEALTHCARESUNHARBOApproved 2026-11-09: SUNHARBO (NDA221291 ORIG1)
2026-11-09FDA approvalapprovedFRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC FMSMULTIBICApproved 2026-11-09: MULTIBIC (NDA219457 ORIG1)
2026-11-09PDUFA date (company-disclosed)date passedImmunome Inc. IMNMPDUFA November 9, 2026 - Immunome Inc.
2026-11-10FDA approvalapprovedEMD SERONOPIMJETMIApproved 2026-11-10: PIMJETMI (NDA220414 ORIG1)
2026-11-10FDA approvalapprovedCMG PHARM CO LTDMEZOFYApproved 2026-11-10: MEZOFY (NDA211448 SUPPL1)
2026-11-12FDA approvalapprovedBIOCON BIOLOGICS INCPEBRILZOApproved 2026-11-12: PEBRILZO (BLA761501 ORIG1)
2026-11-13Complete response lettercomplete responseSummit Therapeutics Inc. SMMTSMT112CRL 2026-11-13: Summit Therapeutics Inc. BLA 761524 (AK112/SMT112 (also referred to by the Applicant as ivonescimab))
2026-11-13FDA approvalapprovedTEVA TEVAIGALMIApproved 2026-11-13: IGALMI (NDA215390 SUPPL3)
2026-11-13FDA approvalapprovedGENENTECHGAZYVAApproved 2026-11-13: GAZYVA (BLA125486 SUPPL44)
2026-11-13FDA approvalapprovedASTRAZENECA UK LTD AZNIMFINZIApproved 2026-11-13: IMFINZI (BLA761069 SUPPL59)
2026-11-13FDA approvalapprovedALEXION PHARMKLYGEFAApproved 2026-11-13: KLYGEFA (BLA761488 ORIG1)
2026-11-13FDA approvalapprovedCYTOKINETICS CYTKMYQORZOApproved 2026-11-13: MYQORZO (NDA219083 SUPPL2)
2026-11-13FDA approvalapprovedBIOGEN BIIBZURZUVAEApproved 2026-11-13: ZURZUVAE (NDA217369 SUPPL4)
2026-11-19FDA AdComscheduledAdCom 2026-11-19: Microbiology Devices Panel of the Medical Devices Advisory Committee
2026-11-22PDUFA date (company-disclosed)pendingCAPRICOR THERAPEUTICS, INC. CAPRPDUFA November 22, 2026 - CAPRICOR THERAPEUTICS, INC.
2026-11-27PDUFA date (company-disclosed)pendingBridgeBio Pharma, Inc. BBIOPDUFA November 27, 2026 - BridgeBio Pharma, Inc.
2026-11-30PDUFA date (company-disclosed)pendingCogent Biosciences, Inc. COGTbezuclastinibPDUFA November 30, 2026 - Cogent Biosciences, Inc. (bezuclastinib)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2BeiGeneNCT03736889 Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsMSI-H/dMMR Solid Tumorsrecruiting200
2026-11 est.P1/P2Aptose Biosciences Inc.NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory AcuteLeukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML; Myelodysplastic Syndrome With Excess Brecruiting240
2026-11 est.P2BioNTech SE BNTXNCT04486378 A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage IColorectal Cancer Stage II; Colorectal Cancer Stage IIIactive not recruiting327
2026-11 est.P3OctapharmaNCT04640142 Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary ImmunodeficiePrimary Immune Deficiencyactive not recruiting50
2026-11 est.P2AbbVie ABBVNCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring ChronicChronic Lymphocytic Leukemia (CLL)recruiting75
2026-11 est.P1/P2BeOne Medicines ONCNCT04973605 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, anRelapsed/Refractory Multiple Myelomarecruiting246
2026-11 est.P3Camurus ABNCT05050942 A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETGastro-enteropancreatic Neuroendocrine Tumoractive not recruiting332
2026-11 est.P1/P2Talaris Therapeutics Inc.NCT05098145 A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic Sclerosiswithdrawn
2026-11 est.P3Immunic AG IMUXNCT05134441 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisMultiple Sclerosisactive not recruiting1121
2026-11 est.P3Immunic AG IMUXNCT05201638 Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisMultiple Sclerosis, Relapsing-Remittingactive not recruiting1100
2026-11 est.P3NewAmsterdam Pharma NAMSNCT05202509 Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseaseAtherosclerotic Cardiovascular Diseaseactive not recruiting9541
2026-11 est.P1/P2Bexion Pharmaceuticals, Inc.NCT05322590 BXQ-350 in Newly Diagnosed Metastatic Colorectal CarcinomaMetastatic Colorectal Carcinoma; Neuropathyactive not recruiting195
2026-11 est.P3Oncternal Therapeutics, IncNCT05431179 A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell LymphomaLymphoma, Mantle-Cell; Lymphoma; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferatwithdrawn
2026-11 est.P2AbbVie ABBVNCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancHigh Grade Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Canceractive not recruiting125
2026-11 est.P2Pharmazz, Inc.NCT05514340 Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic EncephalopathyHypoxic-Ischemic Encephalopathy; Neonatal Asphyxia; Neonatal Encephalopathyrecruiting40
2026-11 est.P1/P2Anbogen Therapeutics, Inc.NCT05532696 Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC PatientsAdvanced Solid Tumor; Non Small Cell Lung Cancer; HER2 Mutationsrecruiting61
2026-11 est.P2IGC Pharma, LLC IGCNCT05543681 Clinical Trial on Agitation in Alzheimer's DementiaAlzheimer Disease; Agitation,Psychomotor; Care Giving Burden; NPS; Aggressionactive not recruiting164
2026-11 est.P1/P2Tyra Biosciences, Inc TYRANCT05544552 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsLocally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Urothelial Carcactive not recruiting310
2026-11 est.P2Stemline Therapeutics, Inc.NCT05596409 ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyMetastatic Breast Canceractive not recruiting61
2026-11 est.P2Atossa Therapeutics, Inc. ATOSNCT05607004 (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast CancerBreast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer; HER2-negative Bractive not recruiting87
2026-11 est.P2Beckley Psytech LimitedNCT05660642 An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant DepressionTreatment Resistant Depressionrecruiting72
2026-11 est.P2AbbVie ABBVNCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab Hepatocellular Carcinomaactive not recruiting130
2026-11 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT06015048 A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.HER2-expressing Advanced Solid Tumorsrecruiting364
2026-11 est.P2TBF Genie TissulaireNCT06038331 Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT OsteoarthritisOsteoarthritis Handactive not recruiting14
2026-11 est.P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid TumorsNSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumorsrecruiting200
2026-11 est.P3CG Oncology, Inc. CGONNCT06111235 A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNon Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial Carcinomaactive not recruiting367
2026-11 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)Nasopharyngeal Carcinomaactive not recruiting386
2026-11 est.P2ReCode TherapeuticsNCT06237335 A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CFCystic Fibrosisactive not recruiting128
2026-11 est.P3medac GmbHNCT06239311 Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.Moderate to Severe Atopic Dermatitisrecruiting277
2026-11 est.P2argenx ARGXNCT06284954 A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With DermatomyositisDermatomyositis; Myositisactive not recruiting3
2026-11 est.P3AkesoNCT06341335 A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaGastric and Gastroesophageal Junction Adenocarcinomarecruiting506
2026-11 est.P3AbbVie ABBVNCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabAtopic Dermatitisactive not recruiting184
2026-11 est.P2Apogee Therapeutics, Inc. APOGNCT06395948 A Study Evaluating APG777 in Atopic DermatitisAtopic Dermatitisactive not recruiting470
2026-11 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNon-Small Cell Lung Canceractive not recruiting406
2026-11 est.P2NewAmsterdam Pharma NAMSNCT06496243 Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) LevelsDyslipidemiasrecruiting69
2026-11 est.P2Jiangsu HengRui Medicine Co., Ltd.NCT06529432 A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic SurgeryLocal Analgesia Via Nerve Blockrecruiting96
2026-11 est.P2BeOne Medicines ONCNCT06637501 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemiaactive not recruiting94
2026-11 est.P3Eli Lilly and Company LLYNCT06662383 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityObesityactive not recruiting800
2026-11 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06668961 A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous CelHead and Neck Squamous Cell Carcinomaactive not recruiting48
2026-11 est.P2Calluna Pharma ASNCT06736990 A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosisactive not recruiting150
2026-11 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06737731 A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid TumorsMalignant Solid Tumorsrecruiting300
2026-11 est.P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06767813 Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic NeoplasmsPancreatic Neoplasmsrecruiting80
2026-11 est.P2Kiora Pharmaceuticals, Inc. KPRXNCT06825702 Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular EdemaMacular Edemarecruiting28
2026-11 est.P1/P2Aldena TherapeuticsNCT06826196 A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia AreataAlopecia Areata (AA)active not recruiting9
2026-11 est.P2ImmunityBio, Inc. IBRXNCT06829823 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNon-muscle Invasive Bladder Cancer (NMIBC)not yet recruiting20
2026-11 est.P2KeyBioscience AGNCT06833749 Efficacy and Safety of KBP-336 in Obese Individuals with OsteoarthritisOsteoarthritis in the Knee; Obesityrecruiting600
2026-11 est.P2Alkermes, Inc. ALKSNCT06843590 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaIdiopathic Hypersomniaactive not recruiting126
2026-11 est.P2AbbVie ABBVNCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized AnxGeneralized Anxiety Disorder (GAD)recruiting315
2026-11 est.P3EirGenix, Inc.NCT06884254 Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor NegatEarly Breast Cancerwithdrawn
2026-11 est.P2Pacira Pharmaceuticals, Inc PCRXNCT06884865 A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the KneeOsteoarthritis (OA) of the Kneerecruiting135
2026-11 est.P3Eli Lilly and Company LLYNCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightType 1 Diabetes; Obesity; Overweightactive not recruiting905
2026-11 est.P3Agitated Solutions, Inc.NCT06938347 Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left ShuntRight-To-Left Shuntrecruiting300
2026-11 est.P3Eli Lilly and Company LLYNCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightType 1 Diabetes; Obesity; Overweightactive not recruiting465
2026-11 est.P3DBV Technologies DBVTNCT07003919 Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)Allergy; Peanut Allergyactive not recruiting480
2026-11 est.P3Wooshin Labottach Co., Ltd.NCT07029516 Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, PsoriasisNail Psoriasis; Nail Damage; Mycosisrecruiting72
2026-11 est.P2BRIM Biotechnology Inc.NCT07078955 A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye DiseaseDry Eye Disease (DED); Keratoconjunctivitis Siccanot yet recruiting99
2026-11 est.P1/P2TYK Medicines, IncNCT07104643 Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)mCRPCnot yet recruiting48
2026-11 est.P2Arthrosi TherapeuticsNCT07116746 Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed PatientsGout; Gouty Arthritis; Hyperuricemia; Gout Chronic; Refractory Gout; Uncontrolled Gout; Tophaceous Gactive not recruiting15
2026-11 est.P3Nanjing Chia-tai Tianqing PharmaceuticalNCT07177859 A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria PatientsParoxysmal Nocturnal Hemoglobinurianot yet recruiting78
2026-11 est.P2SciNeuroNCT07199777 A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME PatientsDiabetic Macular Edema; DMEnot yet recruiting60
2026-11 est.P2Eli Lilly and Company LLYNCT07215312 A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinDiabetes Mellitus, Type 2active not recruiting100
2026-11 est.P3Lynk Pharmaceuticals Co., LtdNCT07237568 A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing SpondylitisAnkylosing Spondylitisrecruiting352
2026-11 est.P3Verrica Pharmaceuticals Inc. VRCANCT07246590 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV); Wartsactive not recruiting302
2026-11 est.P3Waterstone Pharmaceutical (Wuhan) Co., LTD.NCT07251309 A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of HyperkalemiaHyperkalemiarecruiting420
2026-11 est.P2Bright Minds Biosciences Pty Ltd DRUGNCT07266324 A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.Prader-Willi Syndromenot yet recruiting16
2026-11 est.P2/P3Nuance HearingNCT07282028 A Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety and EfficacyHearing Loss Mixedrecruiting89
2026-11 est.P2Avistone Biotechnology Co., Ltd.NCT07336732 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR MutationsNon-Small-Cell Lung Cancerrecruiting40
2026-11 est.P2Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07398859 Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic RhinitisSeasonal Allergic Rhinitisrecruiting300
2026-11 est.P2Shandong Suncadia Medicine Co., Ltd.NCT07470983 A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary AldosteronismPrimary Aldosteronismactive not recruiting61
2026-11 est.P2Traws Pharma, Inc. TRAWNCT07503405 Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge ModelInfluenzanot yet recruiting165
2026-11 est.P3Sinovac Biotech Co., Ltd SVANCT07505888 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 YearsEpidemic Meningitis; Meningococcal Vaccinesactive not recruiting660
2026-11 est.P2Eli Lilly and Company LLYNCT07511816 A Study of LY4515100 in Participants With Pain Following Third Molar RemovalAcute Pain; Molar; Molar, Third; Surgery, Oralrecruiting212
2026-11 est.P2NeuShen TherapeuticsNCT07521683 A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of SchizophreniaSchizophrenia(Acute)enrolling by invitation150
2026-11 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT07551739 A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Orthopedic SurgeryPain After Surgerynot yet recruiting200
2026-11 est.P3Alcon Research ALCNCT07578363 An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in AdultsOcular Hyperemiarecruiting178
2026-11 est.P3Colgate Palmolive CLNCT07605338 To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis.Plaque, Dental; Gingivitisactive not recruiting85
2026-11-01 est.P2ML Bio Solutions, Inc.NCT04800874 Study of BBP-418 in Patients With LGMD2ILGMD2Iactive not recruiting14
2026-11-01 est.P2/P3Mirror Biologics, Inc.NCT05033522 Immunotherapy for Advanced Liver CancerHepatocellular Carcinomasuspended150
2026-11-01 est.P3EpygenixNCT05066217 An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut SyndromeLennox Gastaut Syndromerecruiting260
2026-11-01 est.P1/P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05584800 Study of ZGGS18 in Patients With Advanced Solid TumorsAdvanced Solid Tumorrecruiting222
2026-11-01 est.P3Scholar Rock, Inc. SRRKNCT05626855 Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of ApitegromabSpinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neuromactive not recruiting238
2026-11-01 est.P3Bristol-Myers Squibb BMYNCT06951698 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderBipolar-I Disorder With Mania or Mania With Mixed Featuresrecruiting274
2026-11-02P2/P3Hoffmann-La RocheNCT05115110 A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)completed97
2026-11-02 est.P2GlaxoSmithKlineNCT05723562 A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal CancerNeoplasms, Rectalactive not recruiting154
2026-11-02P3AstraZeneca AZNNCT06015737 A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusCutaneous Lupus Erythematosusactive not recruiting339
2026-11-02 est.P2Regeneron Pharmaceuticals REGNNCT06190951 A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaMelanomaactive not recruiting151
2026-11-02 est.P3Bristol-Myers Squibb BMYNCT06951711 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)Bipolar Disorder Type I With Mania or Mania With Mixed Featuresrecruiting274
2026-11-02 est.P2Keymed Biosciences Co.LtdNCT07166211 Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)Chronic Spontaneous Urticaria (CSU)recruiting48
2026-11-03P1/P2Solid Biosciences Inc. SLDBNCT03368742 Microdystrophin Gene Transfer Study in Adolescents and Children With DMDDuchenne Muscular Dystrophycompleted12
2026-11-03 est.P3Novartis Pharmaceuticals NVSNCT05677451 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response Chronic Spontaneous Urticariaactive not recruiting100
2026-11-03P2/P3Gilead Sciences GILDNCT06544733 Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuHIV-1-Infectionterminated80
2026-11-03P2Rhythm Pharmaceuticals, Inc. RYTMNCT06772597 A Study of Setmelanotide in Patients With Prader-Willi SyndromePrader-Willi Syndrome; Obesity; Hyperphagiaactive not recruiting18
2026-11-03P3SandozNCT06847724 Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisRelapsing Multiple Sclerosisactive not recruiting183
2026-11-04P3THPharm Corp.NCT06647745 A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THPType 2 Diabetes; Hypertensionactive not recruiting222
2026-11-04 est.P3CMG Pharmaceutical Co. LtdNCT06772168 Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and DyslipidemiaDyslipidemia; Type 2 Diabetesrecruiting240
2026-11-04P3Colgate Palmolive CLNCT07917507 Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and GingivitisPlaque; Gingivitiscompleted84
2026-11-05 est.P2Incyte Corporation INCYNCT04509700 Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)B-Cell Malignanciesactive not recruiting112
2026-11-05 est.P1/P2AstraZeneca AZNNCT07336446 A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer DrugsProstate Canceractive not recruiting6
2026-11-06 est.P2Novartis Pharmaceuticals NVSNCT06004661 Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionMetastatic Castration-Resistant Prostate Cancer (mCRPC)active not recruiting23
2026-11-06 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT07150988 A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque PsoriasisPsoriasisnot yet recruiting150
2026-11-09 est.P3LEAF4Life, Inc.NCT06640777 Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndromenot yet recruiting310
2026-11-10 est.P1/P2HELP Therapeutics Co., Ltd.NCT06340048 Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart FailureHeart Failureactive not recruiting36
2026-11-10 est.P3LaNova Medicines Zhejiang Co., Ltd.NCT06351020 LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.Locally Advanced or Metastatic GC and GCJ Adenocarcinomaactive not recruiting387
2026-11-10 est.P3Gan & Lee Pharmaceuticals.NCT07165223 A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal InsulinDiabetesrecruiting300
2026-11-11 est.P2Precigen, Inc PGENNCT06157151 PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerCervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; Recurrent Cervical Carcinoma; Metastrecruiting24
2026-11-11 est.P3Tasly Pharmaceutical Group Co., LtdNCT06753890 Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)Diarrhea-predominant Irritable Boewl Syndromenot yet recruiting520
2026-11-12 est.P2Pfizer PFENCT05995964 A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisAtopic Dermatitisactive not recruiting507
2026-11-12 est.P3Qilu Pharmaceutical Co., Ltd.NCT06671548 Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsHeavy Menstrual Bleeding; Uterine Fibroidsrecruiting120
2026-11-12 est.P2Longbio Pharma (Suzhou) Co., Ltd.NCT07603713 Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe PeriodontitisPeriodontitisnot yet recruiting100
2026-11-13 est.P1/P2Regeneron Pharmaceuticals REGNNCT04626635 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersAdvanced Solid Tumorsactive not recruiting548
2026-11-13 est.P3Hoffmann-La RocheNCT05646862 A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-NegatiBreast Cancerrecruiting420
2026-11-13 est.P1/P2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06682611 Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Unresectable Locally Advanced or Metastatic Solid Tumorsnot yet recruiting380
2026-11-13 est.P2Regeneron Pharmaceuticals REGNNCT07431086 Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USOverweight or Obesityactive not recruiting120
2026-11-15 est.P2PolyActiva Pty LtdNCT06964191 Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular HypertensionGlaucoma, Open-Angle; Ocular Hypertensionactive not recruiting75
2026-11-15 est.P3Achieve Life Sciences QUITNCT07392125 Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E CigarettesVaping Cessationnot yet recruiting800
2026-11-15 est.P2ImmunityBio, Inc. IBRXNCT07492888 Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)Acute Respiratory Distress Syndrome; Severe Community-Acquired Pneum; Sepsis; Lymphopenia / Immunopawithdrawn
2026-11-17 est.P2AstraZeneca AZNNCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcirecruiting226
2026-11-17 est.P2Novartis Pharmaceuticals NVSNCT06894511 An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCMetastatic Castration Resistant Prostate Cancer (mCRPC)active not recruiting7
2026-11-18 est.P2/P3Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairNCT01064466 Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide PolymorphismsSmall Cell Lung Canceractive not recruiting600
2026-11-18 est.P2/P3Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairNCT03348670 Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide PolymorphismsProstate Canceractive not recruiting600
2026-11-18 est.P3Bristol-Myers Squibb BMYNCT05946941 A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeSjögren's Syndromeactive not recruiting774
2026-11-18 est.P2/P3Medicine Invention Design, IncNCT05987956 Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsALK-Positive Non-Small Cell Lung Cancer (NSCLC)active not recruiting600
2026-11-18 est.P2Hoffmann-La RocheNCT06450639 A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)Duchenne Muscular Dystrophyactive not recruiting30
2026-11-18 est.P2ToLymph Inc.NCT06693336 An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lung Cancer (NSCLC)recruiting42
2026-11-19 est.P2Hoffmann-La RocheNCT06402838 A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)Alzheimer's Diseaseactive not recruiting256
2026-11-19 est.P2Janssen Research & Development, LLCNCT07230860 A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisDermatitis, Atopicactive not recruiting189
2026-11-20 est.P3Merck Sharp & Dohme LLC MRKNCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer Endometrial Neoplasmsactive not recruiting990
2026-11-20 est.P2Incyte Corporation INCYNCT05851443 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaModerate to Severe Asthmaactive not recruiting247
2026-11-20 est.P2Skye Bioscience, Inc. SKYENCT06577090 Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs PlaceboObesityactive not recruiting136
2026-11-21 est.P3Changchun GeneScience Pharmaceutical Co., Ltd.NCT07124221 A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate TabletsHyperprolactinemiarecruiting382
2026-11-22 est.P1/P2Resverlogix CorpNCT03160430 A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With HemodialysisKidney Failure, Chronicnot yet recruiting44
2026-11-22 est.P2Shanghai Henlius BiotechNCT06839066 A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyNasopharyngeal Carcinoma (NPC)recruiting70
2026-11-22 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT07533786 A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal SurgeryPain After Surgeryrecruiting200
2026-11-23 est.P2GlaxoSmithKlineNCT06567782 A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient Neoplasms, Colonrecruiting120
2026-11-23 est.P3GlaxoSmithKlineNCT06693895 A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeChickenpoxrecruiting750
2026-11-23 est.P3GlaxoSmithKlineNCT07596199 A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant WomenDiphtheria-Tetanus-acellular Pertussis Vaccinesactive not recruiting102
2026-11-24 est.P3EMD Serono Research & Development Institute, Inc.NCT03815643 Avelumab Program Rollover StudySolid Tumorsactive not recruiting205
2026-11-24 est.P1/P2AstraZeneca AZNNCT06267729 Study of AZD0754 in Participants With Metastatic Prostate CancerMetastatic Prostate Cancerrecruiting60
2026-11-24 est.P3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06585787 A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Alzheimer Diseaserecruiting406
2026-11-24 est.P2Tectonic Therapeutic TECXNCT06616974 A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)Pulmonary Hypertension; Heart Failure With Preserved Ejection Fractionactive not recruiting191
2026-11-24 est.P3HTA Co., Ltd.NCT07057622 A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETsNETS Ga68 Lu177recruiting184
2026-11-24 est.P1/P2CanSino Biologics Inc.NCT07600983 Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)Streptococcus Pneumoniae Infectionrecruiting854
2026-11-25 est.P3Beijing InnoCare Pharma Tech Co., Ltd.NCT06775860 ICP-332 in Subjects With Moderate to Severe Atopic DermatitisAtopic Dermatitisrecruiting552
2026-11-25 est.P3Sanofi SNYNCT07216079 Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanImmune Thrombocytopeniaactive not recruiting3
2026-11-26 est.P3Tesaro, Inc.NCT03981796 A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced EndomeNeoplasmsactive not recruiting785
2026-11-26 est.P3Shaanxi Micot Pharmaceutical Technology Co., Ltd.NCT07122401 Study of MT1013 for the Treatment of Patients With Secondary HyperparathyroidismSecondary Hyperparathyroidism, Chronic Kidney Diseaserecruiting424
2026-11-28 est.P3Haisco Pharmaceutical Group Co., Ltd.NCT06660992 A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis BronchiectasisNon-cystic Fibrosis Bronchiectasisrecruiting669
2026-11-28 est.P2TrueBinding, Inc.NCT06773962 A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's DiseaseParkinson's Disease (PD)active not recruiting62
2026-11-28 est.P3Sanofi SNYNCT07103148 A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric PopulationYellow Fever Immunizationactive not recruiting2440
2026-11-29 est.P3Pfizer PFENCT06641466 A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigraineMenstrual Migrainerecruiting723
2026-11-30 est.P1/P2Neonc Technologies, Inc. NTHINCT02704858 Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaGlioblastoma Multiformeactive not recruiting49
2026-11-30 est.P3Hoffmann-La RocheNCT03148418 A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Canceractive not recruiting382
2026-11-30 est.P1/P2BeyondBio Inc.NCT03579836 Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic CancerLocally Advanced or Metastatic Pancreatic Cancerrecruiting75
2026-11-30 est.P1/P2CelgeneNCT03989414 A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments inMultiple Myelomaactive not recruiting424
2026-11-30 est.P2Genentech, Inc.NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Canceractive not recruiting99
2026-11-30 est.P1/P2BeyondBio Inc.NCT05093907 A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal CancerMetastatic Colorectal Cancerrecruiting27
2026-11-30 est.P1/P2Amgen AMGNNCT05094336 A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Advanced MTAP-null Solid Tumorsactive not recruiting329
2026-11-30 est.P1/P2ModernaTX, Inc.NCT05095727 A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)Glycogen Storage Diseaseactive not recruiting15
2026-11-30 est.P2NeuroPace NPCENCT05339126 RNS System LGS Feasibility StudyEpilepsy; Lennox Gastaut Syndrome; Lennox-Gastaut Syndrome, Intractable; Seizures; Seizures, Generalactive not recruiting24
2026-11-30 est.P3Pharming Technologies B.V. PHARNCT05438407 Pediatric Patients Aged 4 to 11 Years With APDSAPDSactive not recruiting15
2026-11-30 est.P3AUG TherapeuticsNCT05462587 A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type IILeukocyte Adhesion Deficiencyrecruiting4
2026-11-30 est.P1/P2OncoC4, Inc.NCT05682443 ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPCMetastatic Castration-resistant Prostate Canceractive not recruiting148
2026-11-30 est.P1/P2Xentria, Inc.NCT05890729 Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary ManifestationsPulmonary Sarcoidosisactive not recruiting32
2026-11-30 est.P2/P3CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.NCT05924776 Plasmodium Immunotherapy for Advanced Ovarian CancerAdvanced Ovarian Cancernot yet recruiting30
2026-11-30 est.P1/P2UniQure Biopharma B.V. QURENCT06063850 AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyMesial Temporal Lobe Epilepsyrecruiting12
2026-11-30 est.P2/P3Cytopeutics Sdn. Bhd.NCT06129175 UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)Acute Ischemic Strokerecruiting80
2026-11-30 est.P1/P2OriCell Therapeutics Co., Ltd.NCT06182696 OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMMRelapsed and/or Refractory Multiple Myelomarecruiting83
2026-11-30 est.P1/P2Bio-Thera SolutionsNCT06341114 A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in PaAdvanced Solid Tumorsactive not recruiting112
2026-11-30 est.P2Aura Biosciences AURANCT06643884 Suprachoroidal Administration in Subjects With Metastases to the ChoroidEye Cancer; Primary Cancerrecruiting24
2026-11-30 est.P1/P2Nuwacell Biotechnologies Co., Ltd.NCT06741098 A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis( KOA)Knee Osteoarthritisnot yet recruiting162
2026-11-30 est.P2Mundipharma Research LimitedNCT06794554 Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment OptionsChronic Pulmonary Aspergillosisactive not recruiting60
2026-11-30 est.P2Takeda TAKNCT06812078 A Study of TAK-360 in Adults With Idiopathic HypersomniaIdiopathic Hypersomniarecruiting96
2026-11-30 est.P3Gritgen Therapeutics Co., Ltd.NCT06833983 To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AHemophilia Arecruiting50
2026-11-30 est.P1/P2Immunocore Ltd IMCRNCT06840119 Phase 1/2 Study of IMC-R117C in Selected Advanced CancersCancer; HLA-A*02:01-positiverecruiting600
2026-11-30 est.P2Takeda TAKNCT06952699 A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Narcolepsy Type 2recruiting88
2026-11-30 est.P3InventisBio Co., LtdNCT06954961 A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerBreast Cancerrecruiting640
2026-11-30 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06968585 A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With TrastuzumabHER2-positive Breast Canceractive not recruiting365
2026-11-30 est.P2AkesoNCT06984718 A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCHCC; Hepatocellular Carcinomanot yet recruiting120
2026-11-30 est.P2AstraZeneca AZNNCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaHepatocellular Carcinomaactive not recruiting114
2026-11-30 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT07122687 IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell LungResectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancerrecruiting170
2026-11-30 est.P2Bavarian NordicNCT07199569 Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsMonkeypox (Mpox)active not recruiting970
2026-11-30 est.P3Saol Therapeutics IncNCT07226258 Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee PainOsteoarthritis Knee Painactive not recruiting150
2026-11-30 est.P2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous NoNon-Small Cell Lung Cancernot yet recruiting120
2026-11-30 est.P1/P2Shanghai JMT-Bio Inc.NCT07280832 Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract TumorsUnresectable Locally Advanced or Metastatic Melanoma; Unresectable Locally Advanced or Metastatic Urrecruiting500
2026-11-30 est.P2Ranok Therapeutics (Hangzhou) Co., Ltd.NCT07303465 To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.KRAS G12D Mutations; Pancreatic Ductal Adenocarcinoma (PDAC)recruiting60
2026-11-30 est.P2Mylan Pharmaceuticals IncNCT07365904 Investigating Ovulation Inhibition for Use as a ContraceptiveContraceptionrecruiting60
2026-11-30 est.P3Taisho Pharmaceutical Co., Ltd.NCT07548840 A Clinical Study of TS-172 in Hyperphosphatemia Patients on HemodialysisHyperphosphatemia Patients on Hemodialysisactive not recruiting34
2026-11-30 est.P2BioAge Labs, Inc. BIOANCT07656727 A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk FactorsObesity and Cardiovascular Riskactive not recruiting160
2026-11-30 est.P3Zhejiang Wenda Pharma Technology LTD.NCT07672561 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate toModerate to Severe Plaque Psoriasisrecruiting375

← 2026-10 | 2026-12 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.